tiprankstipranks
Syros Pharmaceuticals reports Q4 EPS (17c), consensus ($1.35)
The Fly

Syros Pharmaceuticals reports Q4 EPS (17c), consensus ($1.35)

Reports Q4 revenue ($754,000), consensus $3.72M. "In 2022, we advanced our efforts to develop new standards of care for the frontline treatment of hematologic malignancies, announcing promising data from our ongoing studies in AML and APL and progressing our pivotal trial in HR-MDS," said Nancy Simonian, CEO of Syros. "We believe we are well-positioned to build on this progress in the year ahead. We are also encouraged by the continued momentum in our global enrollment for SELECT-MDS-1. As evidenced by the FDA’s recent decision to grant Fast Track Designation to tamibarotene for HR-MDS, there is a clear need for new therapies that can address the needs of people living with this progressive and devastating disease and we are working with urgency, together with physicians around the world, to recruit and enroll the SELECT-MDS-1 trial. In addition, we have initiated the randomized portion of the SELECT-AML-1 Phase 2 trial and are actively screening patients. We expect to report initial data from SELECT-AML-1 in the fourth quarter of this year and to provide an update on the development path and timing for further evaluation of SY-2101 in a registration-enabling study in APL in the second half of this year."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on SYRS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles